27 results
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
”), composed of Dr. Andrew Levin, Dr. Liam Ratcliffe, and Simon Tate, to oversee Eliem’s review of its existing program and pipeline and the Eliem Board’s … of independent, disinterested directors to oversee the process related to any potential transaction with Tenet.
On February 8, 2024, management of Tenet
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
Committee”), composed of Dr. Andrew Levin, Dr. Liam Ratcliffe, and Simon Tate, to oversee Eliem’s review of its existing program and pipeline … committee of independent, disinterested directors to oversee the process related to any potential transaction with Tenet.
On February 8, 2024, management
DEFA14A
ELYM
Eliem Therapeutics Inc
11 Apr 24
Additional proxy soliciting materials
8:10am
.” The Investors shall have the right to select one legal counsel to review and oversee any registration or matters pursuant to this Section 2(e), including
8-K
EX-10.5
kxxglqjsoaxara40
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
fe02beb5
18 Mar 24
Other Events
6:34pm
DEF 14A
udaxe5sk
8 Apr 22
Definitive proxy
4:20pm
10-K
gzutfw
7 Mar 22
Annual report
4:03pm
10-Q
nix6y0 aydlh
13 Sep 21
Quarterly report
4:01pm
424B4
n9w ww93h
11 Aug 21
Prospectus supplement with pricing info
5:05pm